Literature DB >> 21051321

Recombinant botulinum neurotoxin A heavy chain-based delivery vehicles for neuronal cell targeting.

Mengfei Ho1, Li-Hsin Chang, Melissa Pires-Alves, Baskaran Thyagarajan, Jordan E Bloom, Zhengrong Gu, Karla K Aberle, Sasha A Teymorian, Yuka Bannai, Steven C Johnson, Joseph J McArdle, Brenda A Wilson.   

Abstract

The long half-life of botulinum neurotoxin serotype A (BoNT/A) in cells poses a challenge in developing post-exposure therapeutics complementary to existing antitoxin strategies. Delivery vehicles consisting of the toxin heavy chain (HC), including the receptor-binding domain and translocation domain, connected to an inhibitory cargo offer a possible solution for rescuing intoxicated neurons in victims paralyzed from botulism. Here, we report the expression and purification of soluble recombinant prototype green fluorescent protein (GFP) cargo proteins fused to the entire BoNT/A-HC (residues 544-1295) in Escherichia coli with up to a 40 amino acid linker inserted between the cargo and BoNT/A-HC vehicle. We show that these GFP-HC fusion proteins are functionally active and readily taken up by cultured neuronal cells as well as by neuronal cells in mouse motor nerve endings.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21051321      PMCID: PMC3038457          DOI: 10.1093/protein/gzq093

Source DB:  PubMed          Journal:  Protein Eng Des Sel        ISSN: 1741-0126            Impact factor:   1.650


  31 in total

1.  Recombinant derivatives of clostridial neurotoxins as delivery vehicles for proteins and small organic molecules.

Authors:  M V Zdanovskaia; G Los; A G Zdanovsky
Journal:  J Protein Chem       Date:  2000-11

Review 2.  Botulinum toxin type A: history and current cosmetic use in the upper face.

Authors:  A Carruthers; J Carruthers
Journal:  Semin Cutan Med Surg       Date:  2001-06

3.  Translocation of botulinum neurotoxin light chain protease through the heavy chain channel.

Authors:  Lilia K Koriazova; Mauricio Montal
Journal:  Nat Struct Biol       Date:  2003-01

4.  Cloning, high-level expression, single-step purification, and binding activity of His6-tagged recombinant type B botulinum neurotoxin heavy chain transmembrane and binding domain.

Authors:  Yu Zhou; Bal Ram Singh
Journal:  Protein Expr Purif       Date:  2004-03       Impact factor: 1.650

Review 5.  Getting muscles moving again after botulinum toxin: novel therapeutic challenges.

Authors:  Patrick G Foran; Bazbek Davletov; Frederic A Meunier
Journal:  Trends Mol Med       Date:  2003-07       Impact factor: 11.951

6.  Identifying and modulating disulfide formation in the biopharmaceutical production of a recombinant protein vaccine candidate.

Authors:  Anne Bouvier; Jaymi Chapline; Renee Boerner; Shanthini Jeyarajah; Susan Cook; Prathima S Acharya; Ian Henderson; Jeffrey L Schrimsher; Scot R Shepard
Journal:  J Biotechnol       Date:  2003-08-15       Impact factor: 3.307

7.  Development of a delivery vehicle for intracellular transport of botulinum neurotoxin antagonists.

Authors:  Michael C Goodnough; George Oyler; Paul S Fishman; Eric A Johnson; Elaine A Neale; James E Keller; William H Tepp; Mike Clark; Stephanie Hartz; Michael Adler
Journal:  FEBS Lett       Date:  2002-02-27       Impact factor: 4.124

Review 8.  Botulinum toxin as a biological weapon: medical and public health management.

Authors:  S S Arnon; R Schechter; T V Inglesby; D A Henderson; J G Bartlett; M S Ascher; E Eitzen; A D Fine; J Hauer; M Layton; S Lillibridge; M T Osterholm; T O'Toole; G Parker; T M Perl; P K Russell; D L Swerdlow; K Tonat
Journal:  JAMA       Date:  2001-02-28       Impact factor: 56.272

9.  Recombinant derivatives of botulinum neurotoxin A engineered for trafficking studies and neuronal delivery.

Authors:  Philip A Band; Steven Blais; Thomas A Neubert; Timothy J Cardozo; Konstantin Ichtchenko
Journal:  Protein Expr Purif       Date:  2010-01-04       Impact factor: 1.650

Review 10.  Neurotoxins affecting neuroexocytosis.

Authors:  G Schiavo; M Matteoli; C Montecucco
Journal:  Physiol Rev       Date:  2000-04       Impact factor: 37.312

View more
  14 in total

1.  Neuronal delivery of antibodies has therapeutic effects in animal models of botulism.

Authors:  Patrick M McNutt; Edwin J Vazquez-Cintron; Luis Tenezaca; Celinia A Ondeck; Kyle E Kelly; Mark Mangkhalakhili; James B Machamer; Christopher A Angeles; Elliot J Glotfelty; Jaclyn Cika; Cesar H Benjumea; Justin T Whitfield; Philip A Band; Charles B Shoemaker; Konstantin Ichtchenko
Journal:  Sci Transl Med       Date:  2021-01-06       Impact factor: 17.956

Review 2.  Cargo-delivery platforms for targeted delivery of inhibitor cargos against botulism.

Authors:  Brenda A Wilson; Mengfei Ho
Journal:  Curr Top Med Chem       Date:  2014       Impact factor: 3.295

3.  Glycine insertion at protease cleavage site of SNAP25 resists cleavage but enhances affinity for botulinum neurotoxin serotype A.

Authors:  Mengfei Ho; Cheong-Hian Goh; Michael C Brothers; Shihua Wang; Ryan L Young; Yuxiang Ou; Juliana Nga-Man Lui; Marinos Kalafatis; Xiuwan Lan; Abigail E Wolf; Chad M Rienstra; Brenda A Wilson
Journal:  Protein Sci       Date:  2012-03       Impact factor: 6.725

4.  Accelerated neuronal cell recovery from Botulinum neurotoxin intoxication by targeted ubiquitination.

Authors:  Chueh-Ling Kuo; George A Oyler; Charles B Shoemaker
Journal:  PLoS One       Date:  2011-05-24       Impact factor: 3.240

5.  Retargeting Clostridium difficile Toxin B to Neuronal Cells as a Potential Vehicle for Cytosolic Delivery of Therapeutic Biomolecules to Treat Botulism.

Authors:  Greice Krautz-Peterson; Yongrong Zhang; Kevin Chen; George A Oyler; Hanping Feng; Charles B Shoemaker
Journal:  J Toxicol       Date:  2011-09-20

6.  Monoclonal Antibodies Targeting the Alpha-Exosite of Botulinum Neurotoxin Serotype/A Inhibit Catalytic Activity.

Authors:  Yongfeng Fan; Isin N Geren; Jianbo Dong; Jianlong Lou; Weihua Wen; Fraser Conrad; Theresa J Smith; Leonard A Smith; Mengfei Ho; Melissa Pires-Alves; Brenda A Wilson; James D Marks
Journal:  PLoS One       Date:  2015-08-14       Impact factor: 3.240

7.  Determinants of pH-dependent modulation of translocation in dermonecrotic G-protein-deamidating toxins.

Authors:  Tana L Repella; Mengfei Ho; Brenda A Wilson
Journal:  Toxins (Basel)       Date:  2013-06       Impact factor: 4.546

8.  Endomicroscopy and electromyography of neuromuscular junctions in situ.

Authors:  Rosalind Brown; Kosala N Dissanayake; Paul A Skehel; Richard R Ribchester
Journal:  Ann Clin Transl Neurol       Date:  2014-10-10       Impact factor: 4.511

9.  Atoxic derivative of botulinum neurotoxin A as a prototype molecular vehicle for targeted delivery to the neuronal cytoplasm.

Authors:  Edwin J Vazquez-Cintron; Maksim Vakulenko; Philip A Band; Larry H Stanker; Eric A Johnson; Konstantin Ichtchenko
Journal:  PLoS One       Date:  2014-01-22       Impact factor: 3.240

10.  Retargeting the Clostridium botulinum C2 toxin to the neuronal cytosol.

Authors:  Benjamin J Pavlik; Elizabeth J Hruska; Kevin E Van Cott; Paul H Blum
Journal:  Sci Rep       Date:  2016-03-30       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.